PATENT CLAIM ANALYSIS

Application Number: 15884884
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["530", "327000"]

Abstract:
The present invention provides the CP-BMP recombinant protein with technical advantages as an intracellular protein therapy for the treatment of bone defects caused by osteogenesis imperfecta, osteoporosis, fracture and osteoctomy in that it could resolve cell-/tissue-permeability and bio-transfer function.

Claim (Index 41):
The recombinant protein according to  claim 31 , wherein the fusion is formed via a peptide bond or a chemical bond.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.10526
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15884651', '15879664', '15432662', '15503117', '12159369']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8091451878429889
- 35 USC 102 Novelty (BERT): 0.6013267559558872
- Combined Prediction Score: 0.7883633446542788
- Mean Citation Score: 545.6922440000002
- Max Citation Score: 639.4984
- Similarity Product: 446.03861654462816

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test